Entasis Therapeutics Stock Price - ETTX

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Entasis Therapeutics Holdings Inc ETTX NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.045 -0.8% 5.55 5.83 5.55 5.55 5.595 18:00:37
Bid Price Ask Price Spread Spread % News
0.01 13.65 13.64 99.93% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
124 6,008 $ 5.62 $ 33,767 9,625 3.9703 - 9.25
Last Trade Time Type Quantity Stock Price Currency
15:59:41 113 $ 5.55 USD

Entasis Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 72.90M 13.13M $ -32.95M 78.69 0.10 13.11M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 8.00 0.20%

more financials information »

Entasis Therapeutics News

Loading Messages....

Latest ETTX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ETTX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week5.845.985.555.724,645-0.29-4.97%
1 Month5.806.285.555.825,123-0.25-4.31%
3 Months9.069.255.036.3715,998-3.51-38.74%
6 Months6.02019.255.036.4712,651-0.4701-7.81%
1 Year6.449.253.97036.0416,534-0.89-13.82%
3 Years13.4513.703.97037.8733,466-7.90-58.74%
5 Years13.4513.703.97037.8733,466-7.90-58.74%

Entasis Therapeutics Description

Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company is engaged in the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. It has the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its products candidate includes etx2514sul, zoliflodacin, etx0282cpdp, and nbp program.


Your Recent History
NASDAQ
ETTX
Entasis Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.